New Integrative Oncology Guidelines Provide Patients More Control Over Their Care

September 14, 2023 9:00 am

Clearity offers psychosocial support through our Steps Through OC program for patients, survivors and caregivers. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC Counselors can help Read more

Clinical trial gives women with gene mutation power over disease

September 8, 2023 9:00 am

When Juana Padron, a 40-year-old mother of four, chose to have a genetic test, going against her friends and family’s advice was the last thing on her mind.

Padron’s aunt died from breast cancer, and she watched her sister endure … Read more

Phase 3 Trial of TTFields and Paclitaxel Misses OS End Point in Ovarian Cancer

August 28, 2023 9:00 am

The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.

Patients with platinum-resistant ovarian cancer given tumor treating fields

Read more

Experts urge study of psilocybin, other psychedelics for cancer-related distress

August 17, 2023 9:00 am

The prevalence of distress among women with late-stage gynecologic cancers calls for well-designed studies to assess the safety and efficacy of psychedelics for this patient population, according to authors of a published commentary.

Psychedelics — specifically psilocybin — have shown … Read more

Long DNA molecules reveal new scar types in HR-deficient cancers

August 16, 2023 9:00 am

DNA can be damaged by toxins, radiation, or even normal cell division, but human cells must continually fix DNA breaks to survive. In cells that cannot repair DNA effectively, changes (mutations) can occur that lead to cancer.

Most cells rely … Read more

Using the immune system to stop ovarian cancer

August 16, 2023 9:00 am

The search for preventions and cures has turned inward—focusing on the immune system to stop ovarian cancer.

Professor Paul Hertzog’s research group at Hudson Institute of Medical Research has been working to expand on their discovery of a naturally occurring … Read more

Elahere for Ovarian Cancer: How to Manage Side Effects

August 15, 2023 9:00 am

A new drug approval is providing hope for many people living with ovarian cancer.

Some women have what is known as “platinum-resistant” cancer, that means the disease is no longer responding to platinum-based chemotherapy, the most common chemo drug used … Read more

New biomarker offers hope for earlier ovarian cancer detection

August 9, 2023 9:00 am

Ovarian cancer is particularly difficult to detect, as the disease often does not produce significant symptoms until it has reached late stages and caused metastasis. New screening methods would help physicians detect ovarian tumors early and dramatically increase the chances … Read more

Proteomics Pathway Diagnostic Helps Identify Platinum-Refractory Ovarian Cancers

August 9, 2023 9:00 am

A new study describes a new diagnostic approach that could help identify the 15% of women with ovarian cancer whose tumors are intrinsically refractory to standard platinum-based therapies, the most common type of chemotherapy for the disease.

Most ovarian cancers … Read more

Batiraxcept Plus Paclitaxel Misses PFS End Point in Platinum-Resistant Ovarian Cancer

August 3, 2023 9:00 am

The addition of batiraxcept to paclitaxel did not significantly improve progression-free survival compared with paclitaxel alone in a prespecified subset of patients with platinum-resistant ovarian cancer who were not previously exposed to bevacizumab, missing the primary end point of the Read more

Aerobic exercise may reduce chemotherapy-induced peripheral neuropathy in ovarian cancer

August 2, 2023 9:00 am

Key takeaways:

  • Women assigned a 6-month intervention reported decreased chemotherapy-induced peripheral neuropathy symptoms.
  • Women in the control group reported a slight increase in symptoms.

A 6-month aerobic exercise intervention significantly improved self-reported chemotherapy-induced peripheral neuropathy among women who underwent chemotherapy … Read more

Upifitamab Rilsodotin Fails to Meet ORR End Point in NaPi2b+ Platinum-Resistant Ovarian Cancer

July 27, 2023 9:00 am

The phase 1/2 UPLIFT trial evaluating the antibody-drug conjugate upifitamab rilsodotin in patients with platinum-resistant ovarian cancer failed to meet its primary end point of investigator-assessed overall response rate in the NaPi2b-positive population.

 

The phase 1/2 UPLIFT trial (NCT03319628) … Read more

Survey Details Concerns, Priorities of Women With Ovarian Cancer

July 13, 2023 9:00 am

By Gianna Melillo

Clearity offers psychosocial support through our Steps Through OC program for patients, survivors and caregivers. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC

Read more

Protein Discovery Aids Ovarian Cancer Detection

July 7, 2023 9:00 am

In Science Advances, Nagoya University scientists publish their work discovering three membrane proteins associated with ovarian cancer. The research team are hopeful that their discovery could improve approaches for detecting and diagnosing the disease.

Reliable biomarkers lacking for ovarian

Read more

How to Treat Gynecologic Cancers During the Chemotherapy Shortage

June 12, 2023 6:48 pm

Three organizations have joined together to provide oncologists with recommendations for how to treat patients with gynecologic cancers in light of current chemotherapy shortages.

The recommendations, which pertain to the shortages of cisplatin, carboplatin, and methotrexate, were released by the … Read more

DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors

June 7, 2023 6:55 am

Key Points:

  • Interim results of the phase 2 trial DESTINY-PanTumor-02 show that T-DXd has broad activity across tumor types and a toxicity profile consistent with previous studies.
  • T-DXd had the lowest activity in pancreatic cancer, and this cohort was stopped
Read more

Avutometinib Plus Defactinib Demonstrates Promising Activity in Recurrent LGSOC

June 6, 2023 7:03 am

Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the … Read more

ImmunoGen’s Elahere Doubles Response Rate Versus Chemo in Phase III Ovarian Cancer Trial

June 4, 2023 9:30 pm

CHICAGO – Twice as many patients with folate receptor alpha (FRα)-positive, advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer responded to ImmunoGen’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) than did patients on chemotherapy in a confirmatory Phase III trial.… Read more

Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

June 4, 2023 6:58 am

Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the … Read more